Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy
- 1 May 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 34 (9-10), 430-438
- https://doi.org/10.1089/hum.2022.081
Abstract
Adeno-associated virus (AAV) based gene therapies are emerging strategies in Duchenne muscular dystrophy (DMD) treatment. Exposure to wild-type AAV can lead to development of neutralizing antibodies (NAb) and block AAV transduction, thereby limiting the delivery of AAV vector-based gene therapy. Therefore, it is imperative to check for the presence of AAV NAbs in a patient who is a candidate for gene therapy. We prospectively enrolled 101 genetically confirmed males with DMD (median age 11 years, 48% ambulatory, 59% on steroids) and performed AAV neutralization assays against AAV2, AAV8, AAV9, and AAVrh74 serotypes. Serotype analysis showed AAV9 (36%) and AAVrh74 (32%) seroprevalence was lower compared to AAV2 (56%) and AAV8 (47%). Interestingly, age was not correlated with NAb titer for any of the capsids. NAb responses were observed at a higher frequency in African American participants and at a lower frequency for Caucasian participants for all four serotypes. Further analysis showed no significant differences in NAb titers depending, regardless of serotype, on whether participants were taking steroids. Finally, we observed higher AAV8, AAV9, and AAVrh74 seroprevalence and significantly higher AAV2 and AAV8 NAb titers in participants that were ambulatory compared to the non-ambulatory participants. Overall, these data identify AAV9 and AAVrh74 as the two serotypes with lower preexisting NAbs in this study’s cohort of 101 males with DMD, possibly showing their utility for future gene therapy applications to treat this cohort men with DMD.This publication has 25 references indexed in Scilit:
- Differential Prevalence of Antibodies Against Adeno-Associated Virus in Healthy Children and Patients with Mucopolysaccharidosis III: Perspective for AAV-Mediated Gene TherapyHuman Gene Therapy Clinical Development, 2017
- Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE MyopathyHuman Gene Therapy, 2017
- Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasionProceedings of the National Academy of Sciences of the United States of America, 2017
- Duchenne and Becker Muscular DystrophiesNeurologic Clinics, 2014
- Humoral Immunity to AAV-6, 8, and 9 in Normal and Dystrophic DogsHuman Gene Therapy, 2012
- Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophiliaGene Therapy, 2011
- Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV VectorsHuman Gene Therapy, 2010
- Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated VirusesThe Journal of Infectious Diseases, 2009
- Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseNature Medicine, 2006
- Mutations on the External Surfaces of Adeno-AssociatedVirus Type 2 Capsids That Affect Transduction andNeutralizationJournal of Virology, 2006